

Press Release

Press release of ProFibrIX BV and Bioceros BV

ProFibrIX to enter in a research collaboration with Bioceros.

Leiden and Utrecht, The Netherlands – April 2, 2007

ProFibrIX BV and Bioceros BV today announced that they have entered into a research collaboration. Bioceros will employ its expertise, experience and know-how in generating and testing new proteins to assist ProFibrIX with its R & D programs. The research collaboration is focused on establishing a dedicated platform for production, purification and characterization of fibrinogen.

Financial terms of the collaboration were not disclosed.


“We are impressed by the know-how of the employees and by the facilities of Bioceros. We expect that this collaboration will significantly accelerate our early stage development programs, while we stay focused on the development of our lead product Fibrocaps™”, stated Dr. Jaap Koopman, CEO of ProFibrIX.

Remco Brandt, CEO of Bioceros, comments: “We are pleased to be working with ProFibrIX. This project fits perfectly in our current strategy to increase our CRO activities in the field of protein production and characterization. It also clearly demonstrates the demand for experienced R&D service providers like Bioceros by small Venture Capital backed companies that like to stay lean and flexible during the first years of development.”

About ProFibrIX BV

ProFibrIX aims to create, develop and market new and innovative healthcare products, based on the unique properties of human fibrinogen. The lead product is Fibrocaps™ a dry powder fibrin sealant that is expected to enter clinical development in the 2nd half of 2008.

The company is also establishing a fibrinogen technology platform that carefully analyzes the structure and function of fibrinogen variants, identifies the most promising therapeutic targets and then develops the most suitable formulation for each application.



About Bioceros BV

Bioceros is headquartered in Utrecht, the Netherlands and founded in 2003. The company is a contract research organization with a focus on collaborative research with other biotechnology companies, pharmaceutical enterprises and academic institutions in the field of immunology, specifically auto-immune diseases, oncology and infectious diseases. In addition the Company provides cell line generation and pilot production services at pre-clinical scale.

For further information, visit www.profibrix.com or www.bioceros.com or contact:

ProFibrIX BV:

Jaap Koopman, Ph.D. (CEO)
Acacialaan 7
2351 CA Leiderdorp
The Netherlands
tel. +31 (0) 6-21628475
jaapkoopman@planet.nl

Bioceros BV:

Remco M. Brandt, M.Sc. (CEO)
Yalelaan 46
3584 CM Utrecht
The Netherlands
tel. +31 (0) 30-253 7910
r.brandt@bioceros.com